GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AIM ImmunoTech Inc (LTS:0A4Y) » Definitions » EV-to-FCF

AIM ImmunoTech (LTS:0A4Y) EV-to-FCF : -0.48 (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is AIM ImmunoTech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, AIM ImmunoTech's Enterprise Value is $10.17 Mil. AIM ImmunoTech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-21.13 Mil. Therefore, AIM ImmunoTech's EV-to-FCF for today is -0.48.

The historical rank and industry rank for AIM ImmunoTech's EV-to-FCF or its related term are showing as below:

LTS:0A4Y' s EV-to-FCF Range Over the Past 10 Years
Min: -7.01   Med: -1.13   Max: 1.26
Current: -0.46

During the past 13 years, the highest EV-to-FCF of AIM ImmunoTech was 1.26. The lowest was -7.01. And the median was -1.13.

LTS:0A4Y's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 8.19 vs LTS:0A4Y: -0.46

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-12-14), AIM ImmunoTech's stock price is $0.2205. AIM ImmunoTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was $-0.470. Therefore, AIM ImmunoTech's PE Ratio (TTM) for today is At Loss.


AIM ImmunoTech EV-to-FCF Historical Data

The historical data trend for AIM ImmunoTech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AIM ImmunoTech EV-to-FCF Chart

AIM ImmunoTech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.42 -3.60 0.22 1.08 -0.45

AIM ImmunoTech Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.07 -0.45 -0.75 -0.62 -0.57

Competitive Comparison of AIM ImmunoTech's EV-to-FCF

For the Biotechnology subindustry, AIM ImmunoTech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AIM ImmunoTech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AIM ImmunoTech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where AIM ImmunoTech's EV-to-FCF falls into.



AIM ImmunoTech EV-to-FCF Calculation

AIM ImmunoTech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=10.167/-21.128
=-0.48

AIM ImmunoTech's current Enterprise Value is $10.17 Mil.
AIM ImmunoTech's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-21.13 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AIM ImmunoTech  (LTS:0A4Y) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

AIM ImmunoTech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.2205/-0.470
=At Loss

AIM ImmunoTech's share price for today is $0.2205.
AIM ImmunoTech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.470.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


AIM ImmunoTech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of AIM ImmunoTech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


AIM ImmunoTech Business Description

Traded in Other Exchanges
Address
2117 SW Highway 484, Ocala, FL, USA, 34473
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

AIM ImmunoTech Headlines

No Headlines